AKBA – akebia therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics (AKBA) was upgraded by Zacks Research from "strong sell" to "hold".
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates [Yahoo! Finance]
Form PRE 14A Akebia Therapeutics, For: Apr 15
Form 4 Akebia Therapeutics, For: Apr 01 Filed by: Vickers Philip J.
Form 3 Akebia Therapeutics, For: Apr 01 Filed by: Vickers Philip J.
Form 8-K Akebia Therapeutics, For: Mar 27
Form SCHEDULE 13G/A Akebia Therapeutics, Filed by: VANGUARD GROUP INC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.